Key takeaways
- Gastrointestinal effects concentrate during dose escalation, not at maintenance.
- Lean-mass loss accompanies fat loss and is the most under-discussed effect.
- All GLP-1s and dual agonists carry a class boxed warning regarding rodent thyroid C-cell tumours.
The common ones
Nausea, vomiting, diarrhoea and constipation are the most frequently reported effects across semaglutide, tirzepatide and liraglutide. They are concentrated during the escalation period, when the dose is stepping up roughly every four weeks.
This timing matters more than the symptoms themselves. Escalation is where most discontinuation happens, which means it is also where most of the money spent on these drugs is wasted — a person who stops at month four has paid for four months and captured very little durable benefit.
Providers that schedule genuine clinical contact during titration — rather than only at intake — are addressing the single highest-value moment in the whole course.
The less common but more serious
Gallbladder events and pancreatitis have been reported at low rates across this class. Rapid weight loss itself is a risk factor for gallstones, independent of the medication.
All of these agents carry a boxed warning regarding thyroid C-cell tumours observed in rodents. Personal or family history of medullary thyroid carcinoma or MEN2 is a standard exclusion — Amazon lists both explicitly.
Several providers exclude people with a history of gastroparesis, inflammatory bowel disease or existing gallbladder disease, since the mechanism slows gastric emptying.
The lean mass problem
Rapid weight reduction carries meaningful loss of lean mass alongside fat mass. This is the least-marketed effect of GLP-1 therapy and arguably the most consequential for long-term outcomes.
It matters more at higher efficacy. Tirzepatide's larger average reductions mean larger absolute lean-mass loss, and it matters most in older people and those with lower baseline muscle.
The countermeasures are unglamorous and well established: adequate protein intake and resistance training throughout, not just after. Alloy is the only provider we verified that explicitly ties its nutrition and exercise support to GLP-1 treatment specifically rather than offering generic wellness content.
Mood and eating behaviour
Appetite suppression is the mechanism, which means these drugs act on eating behaviour directly. For someone with a history of disordered eating, that interaction deserves genuine clinical attention rather than a checkbox.
PlushCare is the only direct-to-consumer provider we verified that publishes a position — it states it does not treat patients with symptoms of an active eating disorder.
If you have a relevant history, raise it explicitly at intake even if you are not asked. An async questionnaire will not surface it on its own.
When to contact a clinician
Severe or persistent abdominal pain, particularly radiating to the back, warrants prompt medical attention — that is the presentation associated with pancreatitis.
Persistent vomiting, signs of dehydration, or inability to keep fluids down are not things to push through during escalation.
This article is general information, not medical advice. Any decision about starting, adjusting or stopping medication belongs with a qualified clinician who knows your history.
Frequently asked questions
What are the most common GLP-1 side effects?
Do GLP-1s cause muscle loss?
Why do most people stop taking GLP-1s?
Who should not take a GLP-1?
Medical disclaimer
This review is editorial research about a commercial service. It is not medical advice, and it is not a recommendation to start, stop or change any treatment. GLP-1 medications are prescription drugs with real contraindications and side effects. Decisions about whether they are appropriate for you belong with a qualified clinician who knows your medical history. Prices and terms in this category change frequently — we publish the date each review was verified and link every source, but you should confirm current details with the provider before purchasing.